ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / TRXB / financials
ZURA (29) KYTX (35) FENC (37) AGMB (45) ⌘ Pro Terminal →

TRex Bio Inc. (TRXB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$13.74 +1.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.75

TRex Bio Inc. (TRXB) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $371.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TRXB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TRXB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, TRex Bio Inc. (NASDAQ: TRXB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $13.74 (+1.63% 1D, market cap $371.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TRXB ranks #347 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TRXB compare to ZURA and KYTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TRXB carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $361.8M). Among the 5-stock peer group, TRXB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TRXB?
▼

For TRex Bio Inc. (TRXB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #347 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.75 (+0.10%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D
Cash (12)Whales (6)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
$17 Bull$13 Base$10 Bear
📬 FREE TRXB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRXB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY TRXB SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($10.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$13.60+6.2% Next Q
Q2 (-2Q)
42
Grade D$14.44-4.5% Next Q
Q3 (-1Q)
44
Grade D$13.79-0.4% Next Q
Current
47
Grade D$13.74-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TRXB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TRXB currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.19) and Max Pain ($14.43) forces dealer call-delta covering toward $17.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRXB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TRXB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How TRXB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$10.4M (0.3% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRXB)

  • ✓Walkthrough of TRXB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TRXB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.86%
2026-11-02O $13.61H $13.92L $13.10C $13.74VOL 54.9K
SMA50: $14.13
$16.80$15.80$14.80$13.79$12.79$13.742026-10-092026-10-152026-10-212026-10-272026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRXB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRXB Butterfly Map → + Track TRXB →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRXB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRXB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TRXB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRXB)

Health Care Rank #347 of 1016 ⚔️ ZURA vs TRXB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRXB vs. ZURA, KYTX, FENC, AGMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TRex Bio Inc. (TRXB) ranks #347 by composite RQD confidence (47/100, grade D) and #490 by equity capitalization ($371.1M). Within this direct 5-issuer industry benchmark cohort, TRXB leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. TRXB currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TRXB ACTIVE
TRex Bio Inc.
D 47/100 — — — +1.63% $371.1M Benchmark Subject
ZURA
Zura Bio Limited (Class A)
E 29/100 — — -35.0% +4.93% $370.9M /zura-vs-trxb →
KYTX
Kyverna Therapeutics Inc.
D- 35/100 — — -35.0% -3.08% $361.8M /kytx-vs-trxb →
FENC
Fennec Pharmaceuticals Inc.
D- 37/100 — — -25.9% -6.48% $383.6M /fenc-vs-trxb →
AGMB
AgomAb Therapeutics NV
D 45/100 — — — -5.79% $391.5M /agmb-vs-trxb →

2. TRXB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

TRex Bio Inc. (TRXB) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $371.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. TRXB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRXB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, TRex Bio Inc. (NASDAQ: TRXB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $13.74 (+1.63% 1D, market cap $371.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TRXB ranks #347 in composite RQD confidence.

How does TRXB compare to ZURA and KYTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TRXB carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $361.8M). Among the 5-stock peer group, TRXB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRXB?

For TRex Bio Inc. (TRXB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #347 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRXB trading relative to its 50-day, 200-day, and 52-week technical levels?

TRXB last traded at $13.74 (+1.63% on volume of 39,182 shares), positioning the stock -3.17% below its 50-day simple moving average ($14.19) and -0.58% below its 200-day simple moving average ($13.82). Across its 52-week range of $13.10 to $16.56, TRXB sits at the 18.5% percentile with a 14-day RSI of 47.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.02 to $15.46).

TRXB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is TRex Bio Inc. (TRXB)?

In Trailing 12 Months, TRXB converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $10.4M in free cash flow (0.3% FCF margin).

Direct Sub-Reports: TRXB RQD Cockpit TRXB 12M Forecast TRXB Earnings & Move TRXB Dividends & DRIP TRXB Insiders & 13F TRXB Whale Options TRXB Profit Sankey TRXB News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TRXB — TRex Bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TRXB scores 47 out of 100, a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12 / 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 6 / 20 (institutional accumulation and options positioning); Insider Conviction at 9 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 7 / 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). Taken together, the weakest pillars are Whale 13F Flow and Macro Regime Fit, while the cash engine is the clearest drag on the composite: the rating reports zero ROIC and zero FCF yield, meaning the rating has no cash-generation strength to lean on. The balance sheet pillar is the relative bright spot, with Altman Z 2.5 and Piotroski F 6/9 supporting a mid-range forensic read. For a prospective investor, the implication is that the score reflects weak current cash economics and only moderate institutional and insider conviction, so any upside case rests on factors outside the scored fundamentals. Valuation tradeoffs cannot be fully assessed because P/E, Forward P/E, EV/EBITDA, and EPS are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, all six items relate to TRex Bio's initial public offering. Headlines reference a "$117M IPO" (Fierce Biotech), a target of "up to $133M in U.S. IPO" (Seeking Alpha), and a "TRex Bio IPO" (Yahoo Finance). Barron's and TradingView items carry generic stock-grade and income-statement headings. Each item carries a YELLOW light and a MARKET WIRE impact label. The feed does not provide the substance of the IPO terms, use of proceeds, or any operating results. Risk watch items include the lack of disclosed financials and the fact that the news flow is concentrated on a single event. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

  • What are the terms and final size of the IPO, and how will proceeds be deployed?
  • What are TRex Bio's revenues, operating income, and net income, and is the company currently generating cash?
  • What is the clinical or commercial pipeline underlying the company, and what are its key milestones?
  • What is the current debt, cash balance, and runway, given the forensic indicators provided?
  • Who holds the stock post-IPO, and what are the lock-up terms for pre-IPO shareholders?

TRXB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TRex Bio Inc. (TRXB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TRXB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TRXB Bull vs. Bear Conversation Board — What's Your Call at $13.74?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TRXB 🐻 50% BEARISH CONVICTION
1. Pick Your Side on TRXB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $14.84 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TRXB (D • RQD 47/100) a Buy at $13.74?

Welcome to the TRXB (TRex Bio Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $10.99 (-20.0%)
Spot @ $13.74

Pump the brakes on TRXB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TRXB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless TRex Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $16.90 (+23.0%)
Spot @ $13.74

TRXB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TRXB, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $13.74 (52-wk range $13.10 - $16.56), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%